A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma

Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments.
info:eu-repo/semantics/published